Ritchie v. Corteva, Inc.

CourtDistrict Court, E.D. North Carolina
DecidedMay 14, 2025
Docket7:23-cv-01465
StatusUnknown

This text of Ritchie v. Corteva, Inc. (Ritchie v. Corteva, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. North Carolina primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ritchie v. Corteva, Inc., (E.D.N.C. 2025).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF NORTH CAROLINA SOUTHERN DIVISION No. 7:23-CV-1114-D ERIC CONKLIN, ) Plaintiff, v. ORDER CORTEVA, INC., et al., Defendants. ; On June 30, 2023, Eric Conklin (“Conklin”) filed a complaint against Corteva, Inc. (“Corteva”), DuPont de Nemours, Inc. (“DuPont”), EIDP, Inc. (“EIDP”), the Chemours Company (“Chemours”), and the Chemours Company FC, LLC (“Chemours FC”) (collectively, “defendants”) [D.E. 1]. On December 5, 2023, defendants moved to dismiss Conklin’s complaint for failure to state a claim [D.E. 21] and filed a memorandum in support [D.E. 22]. See Fed. R. Civ. P 12(b)(6). On December 18, 2023, Conklin amended his complaint [D.E. 23]. Conklin alleged: (1) negligence, (2) gross negligence, (3) negligence per se, (4) public nuisance, (5) private nuisance, (6) trespass to real property, and (7) trespass to chattel. See [D.E. 23] JJ 71-100. On December 29, 2023, defendants moved to dismiss Conklin’s amended complaint for failure to state a claim [D.E. 24] and filed a memorandum in support [D.E. 25]. See Fed. R. Civ. P. 12(b)(6). On August 2, 2024, Conklin responded in opposition [D.E. 38]. On August 16, 2024, defendants replied [D.E. 39]. On September 19, 2024, the court granted in part and denied in part defendants’ motion to dismiss for failure to state a claim [D.E. 40]. See Conklin v. Corteva, Inc., No. 7:23-CV-1114, 2024 WL 4242797 (E.D.N.C. Sept. 19, 2024) (unpublished). Conklin’s claims for negligence, gross negligence, private nuisance, and trespass to real property survived. See id. at *1.

On February 14, 2025, defendants moved for entry of a case management order requiring Conklin and the plaintiffs in seven other related cases to submit expert declarations confirming their injuries and proximate causation [D.E. 55], filed a memorandum in support [D.E. 56], and submitted a proposed case management order [D.E. 55-1]. On March 17, 2025, Conklin responded in opposition [D.E. 57]. On March 31, 2025, defendants replied [D.E. 58]. As explained below, the court grants defendants’ motion for entry of a case management order requiring plaintiffs to submit expert declarations confirming their injuries and proximate causation. I. Conklin is the plaintiff in case no. 7:23-CV-1114. Conklin is one of 60 plaintiffs currently pursuing claims against the defendants in this court in eight related cases. See Eric Conklin v. Corteva, Inc. et al., (7:23-CV-1114); Beverly Brown, et al., v. Corteva, Inc. et al., (7:23-CV-1409); Page Ritchie, et al., v. Corteva, Inc., et al., (7:23-CV-1465); Berdie E. Boone, et al., v. Corteva, Inc., et al., (7:23-CV-1473); Amy Godwin, et al., v. Corteva, Inc., et al., (7:23-CV-1500); Devon Bartholomew, et al., v. Corteva, Inc., et al., (7:23-CV-1592); Steven Aaron, et al., v. Corteva, Inc., et_al., (7:23-CV-1599); Constance Baker, et _al., v. Corteva, Inc., et_al., (7:23-CV-1666) (collectively, the “eight related cases”). Because the eight related cases involve the same claims and defendants, this order refers to the individual plaintiffs collectively as “plaintiffs.” Likewise, because the eight related cases mirror one another, the defendants have filed this motion in each related case and plaintiffs have, likewise, opposed defendants’ motion in each related case. See Eric Conklin v. Corteva, Inc. et al., (7:23-CV-1114) [D.E. 55]; Beverly Brown, et al., v. Corteva, Inc. et al., (7:23-CV-1409) [D.E. 52]; Page Ritchie, et al., v. Corteva, Inc., et al., (7:23-CV-1465) [D.E. 54]; Berdie E. Boone, et al.. v. Corteva, Inc., et al., (7:23-CV-1473) [D.E. 58]; Amy Godwin, et al., v. Corteva, Inc., et al., (7:23-CV-1500) [D.E. 52]; Devon Bartholomew, et al., v. Corteva, Inc., et al., (7:23-CV-1592) [D.E. 50]; Steven Aaron, et al., v. Corteva, Inc., et al., (7:23-CV-1599) ,

[D.E. 64]; Constance Baker, et al., v. Corteva, Inc., et al., (7:23-CV-1666) [D.E. 72]. This order resolves defendants’ identical motions in the eight related cases and recounts plaintiffs’ general factual allegations concerning defendants’ motions. The Fayetteville Works Plant is located in Bladen County, North Carolina. See Am. Compl. [D.E. 23] | 25. The Fayetteville Works Plant manufactures films, fibers, and specialty chemicals in five discrete manufacturing areas including fluromonomers/nafion, polymer processing aid (“PPA”), butacite, SentryGlas, and polyvinvyl fluoride (“PVF”). See id. at 27. Since the 1980s, defendants have used PFAS at the Fayetteville Works Plant. See id. at 30-32. A drainage channel used at the outfall area exists from the Fayetteville Works Plant to the Cape Fear River. See id, at 25. This segment of the Cape Fear River constitutes surface water, “making it a source of water supply for drinking, culinary, or food processing purposes, as well as for aquatic life propagation and maintenance of biological integrity (including fishing and fish), wildlife, secondary recreation, and agriculture.” Id. at § 26 (cleaned up). The wastewater from the Fayetteville Works Plant flows from the outfall area through wastewater treatment plants. See id. at □ 25-26. The wastewater treatment plant dilutes the water with hundreds of thousands of gallons of Cape Fear River water and then discharges the diluted chemicals into the Cape Fear River. See id. While the dilution makes it harder to detect the chemicals, it does not reduce the contaminants flowing into the river. See id. at ]27. Additionally, the Fayetteville Works Plant has one stack that releases airborne emissions of perfluoroalkyl, which results in additional water contamination of the Cape Fear River. See id. at J 28. Scientists have linked exposure to polyfluoroalkyl substances (“PFAS”) to kidney cancer, testicular cancer, prostate cancer, ovarian cancer, non-Hodgkin’s lymphoma, liver disease, ulcerative colitis, thyroid disease, hypercholesterolemia, and pregnancy-induced hypertension. See id. at § 29. PFAS remain in the environment, particularly in water, for years. See id. at J 36.

Defendants use Nafion byproducts 1 and 2 in their manufacturing process. See id. at { 30. In the early 2000s, following pressure from government regulators, defendants replaced perfluorooctanoic acid (“PFOA”) with hexafluoropropylene oxide dimer acid (“GenX”) in its manufacturing process for safety reasons. See id. Defendants used GenX despite animal studies dating back to 1963 reflecting an association between GenX and various negative health impacts on laboratory animals. See id. at 132. These animal studies indicate that GenX may be as toxic or more toxic than PFOA and could adversely affect humans. See id, at J 33. Even with this knowledge, defendants continued to discharge GenX into the Cape Fear River. See id. at □ 34. GenX remains in humans’ bloodstream longer than other PFAS, requiring testing other biomarkers to determine GenX exposure over time. See id. at ] 36. In November 2016, North Carolina State University researchers published a study identifying GenX and other PFAS in the Cape Fear River’s water at King’s Bluff from June 14, 2013, to December 2, 2013. See id. at 37-39. GenX levels reached 4,500 parts per trillion and averaged at 631 parts per trillion, exceeding the state’s safety standard of 140 parts per trillion. See id. at | 37. On June 19, 2017, environmental regulators found GenX in quantities exceeding the state’s safety standard at four wastewater treatment plants at Bladen Bluffs, NW Brunswick, Pender County, and CFPU Sweeney. See id. at ¢ 40. On June 20, 2017, Chemours announced it would capture, remove, and safely dispose of the contaminated wastewater. See id. Nonetheless, “[v]ery recent testing” shows that plants and vegetables near the Fayetteville Works Plant remain contaminated, meaning that residents potentially consumed PFAS discharged from the Fayetteville Works Plant, Id. at 741.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Acuna v. Brown & Root Inc.
200 F.3d 335 (Fifth Circuit, 2000)
In Re Rezulin Products Liability Litigation
441 F. Supp. 2d 567 (S.D. New York, 2006)
Abbatiello v. Monsanto Co.
569 F. Supp. 2d 351 (S.D. New York, 2008)
Doe v. Ortho-Clinical Diagnostics, Inc.
440 F. Supp. 2d 465 (M.D. North Carolina, 2006)
Steering Committee v. Exxon Mobil Corp.
461 F.3d 598 (Fifth Circuit, 2006)
Dier v. Merck & Co.
388 F. App'x 391 (Fifth Circuit, 2010)
In re Digitek® Product Liability Litigation
264 F.R.D. 249 (S.D. West Virginia, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
Ritchie v. Corteva, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/ritchie-v-corteva-inc-nced-2025.